(TEM) Tempus AI, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TEM) Tempus AI, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Tempus AI, Inc. BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Clinical genomic sequencing
Clinical genomic sequencing is Tempus AI, Inc.’s clear Star: it is the core oncology engine behind physician orders and the company’s precision-medicine moat. In Tempus AI, Inc.’s latest public results, 2024 revenue reached $693.4 million, showing strong demand for this diagnostic base. As the tumor-testing market keeps expanding, this is the most proven leader in the mix.
Insights data licensing
Insights data licensing turns Tempus AI’s de-identified clinical, molecular, and imaging data into repeatable revenue, and pharma and biotech use it for research, biomarker work, and model building. It is a Star-like asset because it scales without matching lab-cost growth. The edge is Tempus AI’s data depth, which is hard to copy.
Trials matching
Trials matching is a Star because it connects patients to pharma-sponsored studies and taps Tempus AI, Inc.’s large clinical network. Oncology enrollment is still a major bottleneck, with up to 80% of trials missing enrollment timelines, so demand stays strong. Tempus AI, Inc.’s data footprint gives it an edge in finding eligible patients faster.
Algos oncology tests
Algos oncology tests fit Tempus AI, Inc. as a strong growth asset: they turn Tempus’ 200+ petabytes of clinical and molecular data and AI layer into better diagnostic output for oncology care. With about 2.0 million new U.S. cancer cases a year, even small gains in test precision and speed can scale fast.
- Data moat supports higher test accuracy
- AI improves diagnostic output
- Large oncology demand base drives growth
These tests sit in a high-growth, high-value BCG position because they can pull share in a market where decision speed matters.
Pharma-biotech customer base
Tempus AI, Inc. uses its pharma-biotech customer base as a Star because it sells analytics and data services that drug makers need more each year. This segment supports recurring, high-value contracts, and it benefits as pharma and biotech teams keep raising data budgets to improve trial design, patient matching, and biomarker work. In BCG terms, it combines strong market growth with a growing share of Tempus AI, Inc.'s commercial value.
- Recurring analytics and data revenue
- High-value pharma-biotech contracts
- Backed by rising drug-data spend
- Supports long-term growth
Tempus AI’s oncology stars are scaling fast on a powerful data moat
Tempus AI, Inc.’s Stars are its fastest-scaling oncology assets: clinical genomic sequencing, insights data licensing, trials matching, and pharma-biotech analytics. 2024 revenue was $693.4 million, and the company said it held more than 200 petabytes of clinical and molecular data, giving these units strong growth and a hard-to-copy data moat.
| Star | Why it fits |
|---|---|
| Sequencing | Core oncology demand |
| Data licensing | Scales with low cost |
What is included in the product
Detailed Word Document
Tempus AI BCG Matrix: pinpoints Stars, Question Marks, Cash Cows, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG Matrix for Tempus AI, Inc. that quickly spots growth bets and cash drains.
Reference Sources
Tempus AI, Inc. Reference Sources provide a credible audit trail that boosts confidence and speeds better investment and strategy decisions.
Cash Cows
PCR analysis
PCR is a standard, high-volume diagnostic workflow used across infectious disease, oncology, and genetic testing, so demand is repeatable and steady. It is far more mature than Tempus AI, Inc.’s newer AI and data products, which makes it a classic cash cow in the BCG Matrix. Because labs keep running PCR tests every day, it can support durable cash generation with lower adoption risk.
Molecular genotyping
Molecular genotyping is a steady cash cow for Tempus AI, Inc. because it sits in routine precision oncology workups, where repeat test volume matters more than fast category growth. Tempus reported full-year 2024 revenue of $693.4 million, up 33% year over year, showing it can monetize core testing demand. The market is mature, but recurring orders can still support durable cash flow.
Anatomical pathology assessments
Tempus AI, Inc.’s anatomical pathology assessments are classic cash cows: they are core lab services with steady, repeat demand from cancer care and drug development. Tempus reported about $700 million in 2024 revenue, showing that its clinical testing base already funds growth. These services fit the cash-cow profile better than newer AI bets because demand is recurring and tied to routine care.
Hub workflow app
Hub is Tempus AI, Inc.’s desktop and mobile workflow app for ordering and receiving results, so it sits close to the clinician’s daily routine. Once it is built into ordering habits and result review, switching costs rise, which makes Hub a sticky support asset. In BCG terms, that fits a Cash Cow profile: modest growth, but reliable usage and retention.
- Embedded in clinician workflow
- Harder to replace after adoption
- Stable, lower-growth support asset
- Helps defend Tempus AI, Inc. accounts
Lens research portal
Lens is a cash-cow style asset for Tempus AI, Inc. because it turns the company’s clinical and molecular data into a repeatable research tool for institutional users. Its value comes from steady re-use, not flashy growth, so it looks more utility-like than Tempus AI, Inc.’s newer bets.
- High reuse by existing institutions
- Supports data discovery and analysis
- More stable demand than new products
Tempus AI’s Cash Cows Powering Its Growth Engine
Tempus AI, Inc.’s cash cows are mature, repeat-use offerings that already generate steady volume: PCR, molecular genotyping, anatomical pathology, Hub, and Lens. Tempus AI, Inc. reported 2024 revenue of $693.4 million, up 33% year over year, showing these core services help fund newer growth bets.
| Cash cow | Why it fits | Data |
|---|---|---|
| PCR | High-volume daily use | Repeat demand |
| Genotyping | Routine oncology workflow | $693.4M 2024 revenue |
| Pathology | Core lab service | 33% YoY growth |
What You See Is What You Get
Tempus AI, Inc. Reference Sources
The Tempus AI, Inc. BCG Matrix preview you’re seeing is the exact same document you’ll receive after purchase. No demo version, no hidden sections—just the full, finalized report ready for immediate use. Once purchased, it’s instantly available for download, editing, or presentation.
Dogs
Non-oncology testing
Non-oncology testing is Tempus AI, Inc.'s most dog-like area because Tempus is still centered on oncology, where its data and AI are strongest. Outside cancer, differentiation is weaker and management gives it less strategic weight, so growth and pricing power are likely lower than in core oncology. In 2025, Tempus still derived the bulk of its value story from oncology-led testing and data, not adjacent assays.
Small bespoke analytics jobs
Small bespoke analytics jobs fit the Dogs bucket because they need expert time but do not scale like Tempus AI’s platform model. Tempus AI’s full-year 2024 revenue was $693.4 million, yet custom one-off work still tends to add little durable share or repeat volume. That usually means weak margins and limited long-term value creation.
Fragmented pathology categories
Fragmented pathology categories sit in a crowded, price-led market, so Tempus AI, Inc. faces thinner margins and slower growth than in oncology data. Unlike its stronger data moat there, these tests are easier to copy and harder to price up, which makes them more like a cash-cow than a growth engine.
Low-usage workflow tools
Tempus AI, Inc.’s Hub and Lens only earn their keep when users build them into daily workflows; at low adoption, they act like add-on tools, not core products. In 2025, that keeps them in dog territory because weak engagement limits cross-sell, retention, and pricing power.
- Deep use creates value.
- Low use means low pull.
- Add-ons do not drive share.
Early trial services outside core oncology
Tempus AI, Inc.'s early trial services outside core oncology are a Dogs-style segment: the matching engine is strongest where its cancer data is dense, but that edge fades in broader settings. Lower share and slower adoption make matching less efficient and less defensible, so the unit likely stays a weak fit versus the core.
- Dense oncology data drives better matching
- Outside core, defensibility drops fast
- Lower share limits scale and adoption
Tempus AI’s Weak Spots: Non-Oncology and Custom Analytics Lag
Tempus AI, Inc.'s Dogs are the low-share, low-growth parts outside core oncology. In 2025, that includes non-oncology testing and small bespoke analytics, where Tempus AI, Inc. lacks the data density that drove $693.4 million 2024 revenue and stronger cancer-led demand.
| Dog area | Why weak | 2024/2025 data |
|---|---|---|
| Non-oncology testing | Thin edge | Core revenue $693.4M in 2024 |
| Custom analytics | Low scale | Low repeat value in 2025 |
Question Marks
Tempus Next
Tempus Next is one of Tempus AI, Inc.’s newer platforms, so it fits the BCG "question mark" profile: high growth potential, but still unproven market share. In healthcare, new tools can scale fast if adoption sticks, yet they often need heavy sales, product, and evidence spend before revenues catch up. That makes Next a likely cash user today, with upside tied to how quickly clinicians and payers adopt it.
AstraZeneca co-development
Tempus AI’s co-development alliance with AstraZeneca sits in the Question Mark bucket: the market is big, but monetization is still early. Tempus reported Q1 2025 revenue of $255.7 million, while AstraZeneca posted 2025 revenue of about $54.1 billion, so the partnership has real scale behind it. It is high-upside, but conversion into recurring Tempus revenue is still unproven.
Pathos AI co-development
Tempus AI’s Pathos AI co-development deal is a clear question mark in the BCG Matrix: it expands Tempus into therapeutic development, but the commercial model is still early. The alliance can widen future data and drug-discovery upside, yet it has not reached the scale or cash generation of Tempus’s core diagnostics business. For now, the unit looks like a high-potential bet that still needs proof.
Non-oncology expansion
Tempus AI, Inc. is still driven by oncology, where its genomic and data assets are deepest, so non-oncology is a Question Mark in the BCG Matrix. If adoption broadens into cardiology, neurology, and rare disease, that base could scale fast, but current share is still early and uneven.
- Core strength: oncology data and tests
- Upside: faster growth beyond cancer
- Risk: market share still forming
Cloud-based pharma analytics
Tempus AI, Inc.’s cloud-based pharma analytics fits a Question Mark: the life-science analytics market is growing fast, but Tempus is still building broad enterprise share. Its cloud tools and data services can scale well, yet adoption across big pharma remains early, so revenue upside is real but market power is not locked in.
- Fast-growing, attractive market
- Cloud model supports scale
- Enterprise share still early
Tempus AI’s Growth Story Is Real—But Proof of Scale Still Lags
Tempus AI, Inc.’s question marks need proof: they sit in fast-growing markets, but share and repeat revenue are still early. Tempus AI’s Q1 2025 revenue was $255.7 million, but newer bets like Tempus Next and Pathos AI still need scale to turn into durable cash flow.
| Item | 2025 data | BCG view |
|---|---|---|
| Tempus AI revenue | $255.7M | Base still growing |
| AstraZeneca revenue | $54.1B | Scale partner |
| Tempus Next | Early stage | Question mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.